Published in Medical Imaging Week, July 10th, 2004
The study measured Melastatin expression using TriPath Imaging's new chromogenic, in-situ hybridization (CISH) method and demonstrated loss of Melastatin expression was an independent prognostic indicator for overall survival in primary melanoma.
This research study's objective was to evaluate the new CISH method developed by TriPath Oncology, a wholly owned subsidiary of TriPath Imaging, for determining Melastatin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.